SWOG clinical trial number
SWOG-9458

Evaluation of Ki-67, p53 and Angiogenesis in Patients Registered to SWOG-8710, Ancillary

Closed
Phase
Accrual
58%
Published
Abbreviated Title
Ancillary
Activated
11/15/1995
Closed
11/01/1998

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2006

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group study

HB Grossman;CM Tangen;C Cordon-Cardo;R Cote;FM Waldman;RW De Vere White;AB Karnad;M Glode;ED Crawford Oncology Reports 16:807-810

2002

SWOG 9458: evaluation of Ki-67, p53 and angiogenesis in patients registered to SWOG 8710

HB Grossman;C Cordon-Cardo;R Cote;FM Waldman;C Tangen;ED Crawford International Journal of Cancer Suppl.13:114 (#O140)

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase